Asthma Management in the Era of Targeted Therapy: Using Phenotype and Biomarkers to Individualize Management
April 23, 2020
April 23, 2021
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Boston University School of Medicine and Rockpointe.
In collaboration with the American Lung Association.
Supported by an educational grant from GlaxoSmithKline and Novartis Pharmaceuticals Corporation.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Physicians — maximum of 1.0 ABAI MOC points
All other health care professionals completing this course will be issued a statement of participation.
This activity is intended for allergists, immunologists, and other clinicians involved in the diagnosis and treatment of patients with severe asthma.
Optimal asthma management involves control of asthma symptoms and reduction of the risk of future asthma exacerbations. However, asthma is a heterogeneous condition and the relationship between daily symptoms and exacerbations varies between different phenotypes and disease severities. Often standard treatment approaches are uniformly used, irrespective of the inflammatory pathway involved and the clinical phenotype. Thus, a significant proportion of patients with severe asthma have inadequately controlled disease.
Patients with severe, persistent asthma (~4%-10% of all asthma cases) are managed by Global Initiative for Asthma (GINA) steps 4 or 5. These guidelines recommend a phenotypic assessment and selection of additional treatment based on the results of testing. This activity, “Asthma Management in the Era of Targeted Therapy: Using Phenotype and Biomarkers to Individualize Management,” will help allergists, immunologists, and other clinicians to diagnose severe asthma, use clinical presentation and biomarker results to determine asthma phenotype, and use this information to develop appropriate individualized management plans for their patients with severe asthma.
This program is designed to address ACGME and NAM competencies, including provide patient-centered care and employ evidence-based practice.
At the conclusion of this activity, participants should be able to:
- Use a patient’s clinical presentation and predictive biomarkers to determine asthma phenotype
- Identify patients with severe asthma using the latest guideline recommendations
- Differentiate among the various subtypes (e.g. eosinophilic), and phenotypes or endotypes of asthma
- Develop personalized management plans incorporating clinical phenotype, biomarkers, and the mechanism of action, efficacy, and safety profiles of available pharmacologic and biologic agents
- Incorporate strategies to engage patients in their care, improving disease understanding and adherence to treatment
Leonard B. Bacharier, MD
Robert C. Strunk Endowed Chair for Lung and Respiratory Research
Professor of Pediatrics and Medicine
Clinical Director, Division of Pediatric Allergy, Immunology, & Pulmonary Medicine
Unit Co-Leader, Patient Oriented Research Unit
St. Louis, MO
Wanda Phipatanakul, MD, MS
Professor of Pediatrics
Harvard Medical School
Director, Asthma Clinical Research Center
Boston Children's Hospital
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please email: firstname.lastname@example.org.
American Board of Allergy and Immunology (ABAI) MOC Points
Diplomates of the American Board of Allergy and Immunology (ABAI) must attest to obtaining 25 hours of Allergy/Immunology-specific CME credits from accredited organizations every year in order to fulfill the lifelong learning component of MOC. Participation in this activity will support board certified allergists and immunologists in contributing towards this MOC requirement set forth by the ABAI.
Disclosures of Conflicts of Interest
This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Faculty and Steering Committee Disclosures
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Leonard B. Bacharier, MD
- Consultant: Aerocrine, AstraZeneca, Boehringer Ingelheim, Genentech/Novartis, GlaxoSmithKline, Sanofi/Regeneron, Teva;
- Speaker: AstraZeneca, GlaxoSmithKline, Novartis, Sanofi/Regeneron;
- Advisory Board: Circassia, Merck, Sanofi/Regeneron, Vectura;
- Data Safety Monitoring Board: DBV Technologies
Wanda Phipatanakul, MD, MS
- Grant/Research Consultant: Genentech, Novartis, Regeneron, Sanofi
Hasmeena Kathuria, MD, BUSM CME Course Director
- Nothing to disclose
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Terry Ann Glauser, MD, MPH; Blair St. Amand; Elizabeth Drury; Natalie Sanfratello, MPH; Cindy Kozlowski, AAS; Cynthia Trubisky, MS Ed, AE-C: Nothing to disclose
Instructions for Participation and Credit
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade of 75%) and program evaluation. Certificates can be printed immediately.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.